Detechta
Detechta is a privately held Brazilian biotechnology company founded in 2015 that develops recombinant antigens, vaccines, and in vitro diagnostic products for human and animal health markets, offering a reagent catalog and end-to-end R&D services from antigen development through technology transfer.
- Company typePrivate
- Founded2015
- HeadquartersBelo Horizonte, Brazil
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Detechta does
Detechta is a privately held Brazilian biotechnology company founded in 2015 and headquartered in Belo Horizonte, Minas Gerais. The company specializes in research, development, and innovation (PD&I) for vaccines, in vitro diagnostics (rapid tests, ELISA, qPCR), and recombinant protein production, addressing both human and animal health markets. Its technical platform spans bioinformatics, synthetic biology, RNA and DNA sequencing, immunoproteomics, epitope mapping, gene cloning, and CRISPR/CAS9 gene manipulation, enabling end-to-end capabilities from recombinant antigen discovery through prototyping, pre-clinical trials, and technology transfer for production and quality control.
The commercial offering combines a reagent product catalog with custom R&D services. Off-the-shelf products include the Proteína A recombinant protein, K39 (leishmania) and NS1 (dengue) recombinant antigens, Ouro Coloidal conjugates for lateral flow assays, Soro Policlonal detection antibodies, and Adjuvante Vacinal. Service lines cover recombinant protein expression and purification, polyclonal antibody production, in vitro and in vivo immunogenicity studies, vaccine antigen and full vaccine development, diagnostic test development, veterinary pre-clinical trials, quality control and stability studies, and performance optimization. Distribution is direct B2B, primarily across Brazil within South America, with engagement via the company website and direct email.
Revenue mechanics, pricing, and customer structure are not publicly disclosed. The business model mixes reagent product sales with fee-for-service R&D contracts aimed at pharmaceutical companies, diagnostic manufacturers, research institutions, and veterinary health businesses. Detechta markets its 100% Brazilian technology status as a domestic-sourcing differentiator for customers seeking to reduce reliance on imported biotechnology inputs, and as of January 2024 was engaged with the state-level development agency Codemge in Minas Gerais.
Detechta firmographics
Firmographics- Name
- Detechta
- Legal name
- Detechta
- Website
- https://detechta.com.br
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Detechta is a privately held Brazilian biotechnology company founded in 2015 that develops recombinant antigens, vaccines, and in vitro diagnostic products for human and animal health markets, offering a reagent catalog and end-to-end R&D services from antigen development through technology transfer.
- Ownership category
- akta.pro rank
Detechta industry classification
Industry- Product category
- Biotechnology / Life Sciences R&D and Reagents
- NAICS
- Scientific Research and Development Services (5417), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Detechta is headquartered
LocationHeadquarters
- HQ city
- Belo Horizonte
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
Detechta business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels2 records
Detechta product offering
Product offeringCore offering
Detechta is a 100% Brazilian biotechnology company that develops and sells recombinant protein products (antigens, polyclonal sera, colloidal gold conjugates, vaccine adjuvants) and provides R&D services for vaccines, in vitro diagnostics (rapid tests, ELISA, qPCR), and recombinant protein production targeting human and animal health markets. Its service offering spans recombinant protein expression and purification, polyclonal antibody production, immunogenicity studies, vaccine antigen and vaccine development, diagnostic test development, preclinical trials, quality control, and technology transfer.
Product overview
Detechta is a 100% Brazilian technology-based company operating in the vaccines, in vitro diagnostic products (rapid tests, ELISA, qPCR), and recombinant protein production segments for human and animal health markets. The company offers a portfolio of research products including recombinant antigens (Proteína A, K39, NS1), colloidal gold conjugates, polyclonal sera, and vaccine adjuvants. Their service portfolio complements these products through the entire vaccine and diagnostic R&D cycle, from recombinant antigen development through prototyping and technology transfer for production and quality control. The product line supports customers developing rapid tests, ELISA assays, and vaccines by providing key immunological reagents.
Differentiator
Problem solved
Functional benefit
Products and services
- Proteína A Recombinant protein product offered by Detechta for research and diagnostic applications in the human and animal health markets.
- K39 (leishmania) Leishmania-specific recombinant antigen product used in diagnostic test development for detecting the disease in human and animal samples.
- NS1 (dengue) Dengue virus non-structural protein 1 (NS1) antigen product used in rapid diagnostic test development for dengue detection.
- Ouro Coloidal (Colloidal Gold) Colloidal gold conjugate product used as a detection reagent in lateral flow rapid diagnostic tests.
- Soro Policlonal (Polyclonal Serum) Polyclonal serum product developed through animal immunization, used as detection antibodies in diagnostic assays.
- Adjuvante Vacinal (Vaccine Adjuvant) Vaccine adjuvant product designed to enhance immune response when combined with vaccine antigens in human and animal vaccine development.
- Recombinant Protein Expression and Purification Service Contract R&D service for expression and purification of recombinant proteins for vaccine and diagnostic applications.
- Polyclonal Antibody Production Service Production of polyclonal antibodies for research and diagnostic purposes.
- In Vitro and In Vivo Immunogenicity Studies Service Comprehensive immunogenicity assessment services for vaccine development.
- Vaccine Antigen Development Service Development of recombinant vaccine antigens for human and animal vaccine applications.
- Vaccine Development Service Vaccine development services for human and animal health markets.
- Diagnostic Test Development Service Development of rapid tests, ELISA, and qPCR diagnostic products for human and animal health.
- Pre-Clinical Trials Service (Veterinary Segment) Pre-clinical trial services for animal health product development.
- Quality Control and Stability Studies Service Quality control and stability studies for vaccine and diagnostic products.
- Performance Optimization Service Performance optimization services for vaccines and diagnostic products.
Companies that use Detechta
Customer profileSegments2 records
Ideal customer profiles3 records
Detechta technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Detechta partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights4 records
Detechta competitors and assessment
Company assessmentDirect peers
- Bio-Manguinhos (Fiocruz): Brazilian government biotechnology institute that produces vaccines and diagnostic kits. Direct comparable in recombinant protein-based vaccine and IVD development with deep expertise in tropical disease antigens, similar to Detechta's product portfolio.
- Instituto Butantan: Brazilian government-affiliated research institute that develops vaccines and immunobiological products for human and animal health. Direct comparable as a Brazilian R&D entity operating in the same vaccine and diagnostic space, though supported by public funding rather than commercial capital.
- Ceva Santé Animale: Global animal health company focused on veterinary vaccines and diagnostics. Comparable in the animal health vaccine and diagnostic segment that Detechta serves, though operating at global scale rather than Brazil-only.
Broad incumbents
- Bio-Rad Laboratories: Global life sciences company with a major diagnostics and life science research products business. Comparable as a supplier of recombinant proteins, polyclonal antibodies, ELISA, and qPCR reagents that compete directly with Detechta's diagnostic development tools.
- Eurofarma Laboratórios: Major Brazilian pharmaceutical company with significant biotechnology operations, including vaccines and biosimilars. Comparable as a large Brazilian player addressing the same domestic market need to reduce import dependence, though Eurofarma operates at significantly greater scale and across broader therapeutic areas.
Others
- Sartorius AG: Global bioprocessing and laboratory products company supplying tools and services to biotech R&D and manufacturing. Comparable as an enabling supplier of bioprocessing and lab technologies that serve similar customers to Detechta in the Brazilian biotech ecosystem.
Emerging players
- IDT Biologika: Biopharmaceutical CDMO and vaccine developer with expertise in viral vaccines and diagnostics. Comparable in offering vaccine R&D and manufacturing services with capabilities in recombinant antigens similar to Detechta's.
- GenScript: Biotechnology company offering recombinant protein production, gene synthesis, and antibody services globally. Comparable as a fee-for-service biotech R&D provider with overlapping capabilities in recombinant antigens and polyclonal antibody production that Detechta also offers.
Regional players
- Wama Diagnóstica: Brazilian manufacturer of diagnostic reagents and ELISA kits. Comparable as a Brazilian IVD reagent supplier serving the same domestic market with similar product categories (ELISA, rapid tests).
- Gold Analisa Diagnóstica: Brazilian in vitro diagnostics company producing reagents and kits for clinical laboratories. Comparable as a regional Brazilian IVD manufacturer with overlapping diagnostic reagent capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Detechta social profiles
Digital presenceDetechta financial estimates
Financial estimateRevenue estimate
Valuation estimate
Detechta leadership team
Management profileNumber of profiles
Detechta funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Detechta M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Detechta
What does Detechta do?
Detechta is a 100% Brazilian biotechnology company that develops and sells recombinant protein products (antigens, polyclonal sera, colloidal gold conjugates, vaccine adjuvants) and provides R&D services for vaccines, in vitro diagnostics (rapid tests, ELISA, qPCR), and recombinant protein production targeting human and animal health markets. Its service offering spans recombinant protein expression and purification, polyclonal antibody production, immunogenicity studies, vaccine antigen and vaccine development, diagnostic test development, preclinical trials, quality control, and technology transfer.
Is Detechta a public or private company?
Detechta is a private company. It is classified as unknown and is currently operating.
When was Detechta founded?
Detechta was founded in 2015. It employs 1 to 10 people.
Where is Detechta based?
Detechta is headquartered in Belo Horizonte, Brazil, in the Latin America region.
Who are Detechta's main competitors?
Direct peers on record are Bio-Manguinhos (Fiocruz), Instituto Butantan and Ceva Santé Animale. Broad incumbents are Bio-Rad Laboratories and Eurofarma Laboratórios. Sartorius AG is listed as an others. Emerging players are IDT Biologika and GenScript. Regional players are Wama Diagnóstica and Gold Analisa Diagnóstica.
Does Detechta have an API?
No public API is recorded for Detechta.
What industry is Detechta in?
Detechta's product category is Biotechnology / Life Sciences R&D and Reagents. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 5417 and its SIC code is 2836.